| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.20897 |
| P698 | PubMed publication ID | 16250039 |
| P50 | author | Adrian M. Di Bisceglie | Q87445433 |
| Kris V. Kowdley | Q110296712 | ||
| P2093 | author name string | Velimir A Luketic | |
| John R Lake | |||
| Thomas D Boyer | |||
| Karen L Lindsay | |||
| Marion G Peters | |||
| Marlyn J Mayo | |||
| Guadalupe Garcia-Tsao | |||
| James L Boyer | |||
| Nathan M Bass | |||
| Melissa J Contos | |||
| Alan F Hofmann | |||
| Maurizio Bonacini | |||
| Robert L Carithers | |||
| Timothy M McCashland | |||
| Scott S Emerson | |||
| Rodney S Markin | |||
| David S Barnes | |||
| Raphael Rubin | |||
| A Brian West | |||
| Santiago J Munoz | |||
| Burton Combes | |||
| A Scott Mills | |||
| Donald E Wheeler | |||
| Enrique J Martinez | |||
| Rowen K Zetterman | |||
| Kent G Benner | |||
| Leonard Rosoff | |||
| Nancy L Flye | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Symmetric group sequential test designs | Q41297580 | ||
| Primary Biliary Cirrhosis Treated with Low-Dose Oral Pulse Methotrexate | Q68481563 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis | Q72036049 | ||
| Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone | Q72227193 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Flexible implementations of group sequential stopping rules using constrained boundaries | Q76350392 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methotrexate | Q422232 |
| primary biliary cholangitis | Q1072420 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1184-1193 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | |
| P478 | volume | 42 |
| Q53591523 | A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. |
| Q36116022 | Advances in pharmacotherapy for primary biliary cirrhosis |
| Q84476629 | American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis |
| Q34457114 | Analysis of the clinical relevance of antimitochondrial antibodies to the β- and γ-subunits of the F1F0-ATPase in patients with primary biliary cirrhosis |
| Q24646460 | Apotopes and the biliary specificity of primary biliary cirrhosis |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q26772310 | Combination antiretroviral studies for patients with primary biliary cirrhosis |
| Q38055205 | Current pharmacotherapy for cholestatic liver disease |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q37829668 | Cutting-edge issues in primary biliary cirrhosis |
| Q38266358 | Diagnosis and management of primary biliary cirrhosis |
| Q34206050 | Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. |
| Q92864604 | Emerging therapies for PBC |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q37559266 | Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient |
| Q48493435 | It's all about bile |
| Q22000839 | Liver involvement in subjects with rheumatic disease |
| Q24235442 | Methotrexate for primary biliary cirrhosis |
| Q42859525 | Methotrexate for primary biliary cirrhosis: who is to be trusted? |
| Q46959070 | Methotrexate for treatment of primary biliary cirrhosis |
| Q43013514 | Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q26824664 | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis |
| Q92135848 | New Therapeutic Targets in Autoimmune Cholangiopathies |
| Q90690599 | NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway |
| Q39216355 | Old and new treatments for primary biliary cholangitis |
| Q28087211 | Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q24186852 | Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis |
| Q37002423 | Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay |
| Q104288323 | Primary biliary cholangitis |
| Q56428273 | Primary biliary cirrhosis |
| Q37783544 | Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q26853649 | Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy |
| Q37072380 | Proposed therapies in primary biliary cholangitis |
| Q46959075 | Reflections on therapeutic trials in primary biliary cirrhosis: a quality of life oriented counter-view. |
| Q42363647 | Risk of liver disease in methotrexate treated patients |
| Q41820056 | The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q26829493 | The diagnosis of primary biliary cirrhosis |
| Q46614923 | The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study |
| Q36914332 | The unfinished business of primary biliary cirrhosis |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q39314534 | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |
| Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
| Q49153341 | Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor |
| Q40898741 | Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study |
Search more.